Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3160 - PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study


10 Oct 2016


Poster display


Ryon Graf


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


R. Graf1, D. Lu1, R. Krupa1, J. Louw1, L. Dugan1, A. Jendrisak1, S. Orr1, K. Bethel1, Y. Wang1, M. Suraneni1, M. Landers1, D. Boffa2, J. Nieva3, L. Bazhenova4, M. Salazar2, S. Makani4, M. Magana4, R. Dittamore1

Author affiliations

  • 1 Translational Research, Epic Sciences, Inc, 92121 - San Diego/US
  • 2 Surgery: Thoracic Surgery, Yale New Haven Health System, New Haven/US
  • 3 Department Of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles/US
  • 4 Department Of Medicine, Moores Cancer Center, San Diego/US


Abstract 3160


Biopsies are currently utilized for profiling (histologic, molecular) of lung cancer prior to treatment. Profiling tumors from circulating markers could avoid invasive procedures and enable more frequent, kinetic disease monitoring. PD-L1 expression on lung cancer biopsy correlates with efficacy of immune checkpoint inhibitors. Using the Epic Sciences PD-L1 assay, we sought to correlate patient outcome with PD-L1(+) circulating CD45(-) cells, prior to its evaluation as a predictive biomarker for immune checkpoint inhibitors.


Peripheral blood was collected from 124 pts with diverse staging and histology at three clinical sites prior to diagnostic biopsy, with some having follow-up draws. All nucleated cells were plated onto glass slides and circulating cells of interest identified by immunofluorescence and morphological features. Prognostic capacity of PD-L1(+) cells (CK + /-, CD45-, PD-L1 + , malignant nuclear morphology) were assessed with Kaplan-Meier and Cox Proportional Hazard (PH) models.


AJCC Stage n = 124 Baseline n = 27 Follow-Up
I 53 7
II 18 4
III 30 8
IV 22 8

When detected, PD-L1 subcellular localization was primarily membranous. Pts with >1 PD-L1(+) cell/mL in baseline samples had worse overall survival (OS) (n = 22/124, mOS: 17.2 months vs. not reached, HR = 3.22, p = 0.0015) and follow-up (n = 5/22 mOS = 2.1 months vs. not reached, HR = 4.25, p = 0.0302). High baseline PD-L1(+) cell burden was additive and independent to AJCC staging in Cox PH models (HR = 2.32, p = 0.0447). Single-cell sequencing is underway.


In a multicenter cohort, circulating PD-L1(+)/CD45(-) cell burden predicted worse OS in pre-biopsy and follow-up lung cancer blood samples. This warrants prospective investigation as a predictive biomarker to PD-1 axis immune checkpoint inhibitors.

Clinical trial identification


Legal entity responsible for the study

National Cancer Institute, Epic Sciences


National Cancer Institute, Epic Sciences


R. Graf, D. Lu, R. Krupa, J. Louw, L. Dugan, A. Jendrisak, S. Orr, K. Bethel, Y. Wang, M. Landers, R. Dittamore: Epic Sciences Employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings